

6. Yandrapalli S, Malik A, Horblitt A, et al. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2. *Cardiol Rev* 2020;28(5):219–235.
7. Sachinidis A, Nikolic D, Stoian AP, et al. Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. *Metabolism* 2020;111:154343. Epub 2020 Aug 16.
8. Pinto LC, Rados DV, Remonti LR, et al. Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis. *J Clin Endocrinol Metab* 2020;105(11):dgaa534.
9. Fillit HM, Rockwood K, Young JB. *Brocklehurst's Textbook of Geriatric Medicine and Gerontology*. Seventh ed. Philadelphia, Elsevier Health Sciences, 2016:1119.
10. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. *Diabetes Care* 2021;44(Suppl. 1):S111–S124.
11. Bhatt AS, Luo N, Solomon N, et al. TECOS Study Group. International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. *Am Heart J* 2019;218:57–65.
12. Singh AK, Singh R. SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs. *Expert Rev Clin Pharmacol* 2017;10(4):429–442.
13. Mohammedi K, Woodward M, Hirakawa Y, et al. ADVANCE Collaborative Group. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. *Cardiovasc Diabetol* 2016;15(1):129.
14. Anděl M, Němcová V, Pavlíková N, et al. Faktory vedoucí k poškození a destrukci B-buněk Langerhansových ostrůvků pankreatu. *Vnitř Lék* 2014;60(9):684–690.
15. Charytan DM, Solomon SD, Ivanovich P, et al. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. *Diabetes Obes Metab* 2019;21(5):1199–1208.
16. Fayman M, Galindo RJ, Rubin DJ, et al. A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes. *Diabetes Care* 2019;42(3):450–456.
17. Mo D, Liu S, Ma H, et al. Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study. *Drug Des Devel Ther* 2019;13:2769–2776.
18. Frias JP, Zimmer Z, Lam RLH, et al. Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study. *Diabetes Obes Metab* 2019;21(5):1128–1135.
19. Müller-Wieland D, Kellerer M, Cypryk K, et al. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. *Diabetes Obes Metab* 2018;20(11):2598–2607.
20. Matthews DR, Paldanius PM, Proot P, et al. Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes. *Diabet Med* 2019;36(4):505–513.
21. Jia S, Wang Z, Ruobing Han 1, et al. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis. *Acta Diabetol* 2021;58(1):5–18.
22. Negro R, Greco EL, Greco G. Alogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients. *Exp Clin Endocrinol Diabetes* 2019;127(4):215–219.
23. Gutierrez JA, Scirica BM, Bonaca MP, et al. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). *Am J Cardiol* 2019;123(1):145–152.
24. Mosenzon O, Leibowitz G, Bhatt DL et al. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. *Diabetes Care* 2017;40(1):69–76.
25. Zannad F, Cannon CP, Cushman WC, et al. EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. *Lancet*. 2015;385(9982):2067–2076.
26. Marx N, Rosenstock J, Kahn SE, et al. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINagliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®). *Diab Vasc Dis Res* 2015;12(3):164–174.
27. Rosenstock J, Perkovic V, Johansen OE. CARMELINA Investigators. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. *JAMA* 2019;321(1):69–79.
28. Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. *Nat Rev Endocrinol* 2020;16(11):642–653.
29. Chun-Xing Li, Shuo Liang, Lingyan Gao, Hua Liu. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis. *PLoS One*. 2021;16(2):e0244689. eCollection 2021.
30. Leite KM, Long AM, Ostroff ML, Borges L, Braden G. A Review of the Renoprotective Effects of Novel Antidiabetic Agents. *J Pharm Pract* 2021;34(1):141–148.
31. Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. *Circulation* 2019;139(11):1384–1395.
32. Mahaffey KW, Neal B, Perkovic V, et al. CANVAS Program Collaborative Group. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). *Circulation* 2018;137(4):323–334.
33. Wiviott SD, Raz I, Bonaca MP et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECA-LARE)-TIMI 58 Trial. *Am Heart J* 2018;200:83–89.
34. Bae JH, Eun-Gee Park, Kim S, Kim SM, Hahn S, Kim NH. Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. *Endocrinol Metab (Seoul)* 2021;36(2):388–400.
35. Linong Ji, Xiaolin Dong, Yiming Li et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial. *Diabetes Obes Metab* 2021;23(2):404–414.
36. Mather KJ, Considine RV, Hamilton L, et al. Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes. *J Clin Endocrinol Metab* 2018;103(9):3456–3465.
37. Zelner TA, Wiviott SD, Raz I, et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. *Circulation* 2019;139(17):2022–2031.
38. Liu X, Huang J, Li J, Mao Q, He J. Effects of Liraglutide Combined with Insulin on Oxidative Stress and Serum MCP-1 and NF-κB Levels in Type 2 Diabetes. *J Coll Physicians Surg Pak* 2019;29(3):218–221.
39. Ba J, Han P, Yuan G, et al. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. *J Diabetes* 2017(7):667–676.
40. Katsiki N, Ferrannini E. Anti-inflammatory properties of anti-diabetic drugs: A „promised land“ in the COVID-19 era? *J Diabetes Complications* 2020; 34(12): 107723. Epub 2020 Aug 26.
41. Yan Yang, Zixin Cai, Jingjing Zhang. DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis. *PLoS One*. 2021;16(5):e0251916. eCollection 2021.
42. Bassendine MF, Bridge SH, McCaughan GW, Gorrell MD. COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity? *J Diabetes* 2020;12(9):649–658. Epub 2020 May 27.